ArticleIntegrative cancer therapies
Integrative Oncology
Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrative Oncology (IO) in France aligns with the definition proposed by the Society for Integrative Oncology, combining conventional cancer treatments with evidence-based complementary therapies within an interdisciplinary, patient-centered framework. Unlike alternative approaches, integrative therapies are used alongside standard oncological care. In France, a wide range of complementary therapies are implemented, with some-such as homeopathy and acupuncture-more widely integrated, reflecting historical use and favorable safety profiles.Over the past decade, IO has developed through diverse organizational models, including hospital-based day care programs, dedicated consultations in cancer centers, and community-based structures. These models provide access to personalized and coordinated care pathways, with no out-of-pocket cost for patients, supported by the national health insurance system or alternative funding sources. In 2023, the French Society for Integrative Oncology was established to structure and promote this approach nationwide and to foster connections with the European branch of the Society for Integrative Oncology.Compared with international models, the French approach appears distinctive in combining hospital-based and community-based structures, thereby facilitating broader accessibility while maintaining coordination with conventional care. This hybrid organization contrasts with predominantly academic models in the United States and more systematically integrated hospital-based systems in countries such as Israel.Available data and patient-reported outcomes suggest improvements in quality of life and treatment adherence. However, marked heterogeneity across programs and a predominantly observational evidence base highlight the need for controlled trials specifically designed to evaluate the particularities of integrative oncology.Overall, integrative oncology in France represents a pragmatic and evolving model that may contribute to reshaping supportive cancer care by combining accessibility, coordination, and patient-centered approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.